San Diego Business Journal

OncoSec Medical Inc., a San Diego-based company developing therapies to treat solid tumors, has received investigational review board approval at UC San Francisco’s Helen Diller Family Comprehensive Cancer Center for a Phase II clinical trial.

Just getting under way, the trial will evaluate the OncoSec Medical System ElectroImmunotherapy for the treatment of cutaneous T-cell lymphoma. UCSF investigators are actively recruiting for this clinical trial that will involve up to 27 patients with cutaneous T-cell lymphoma, a class of non-Hodgkin’s lymphoma that appear as skin lesions.

The trial’s primary endpoint is to assess local and distant response rate following treatment of cutaneous T-cell lymphoma lesions with a DNA-based cytokine coded for the immune stimulating agent interleukin-12 and electroporation.

“The initiation of this study will mark the first time patients suffering from cutaneous T-cell lymphoma will be treated with an immunotherapy delivered using electroporation,” said OncoSec President and CEO Punit Dhillon.

OncoSec Medical System ElectroImmunotherapy utilizes OncoSec’s technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells, which increases DNA IL-12 uptake into these cells.